2 - Qatar Critical Care Conference Proceedings
  • ISSN: 0253-8253
  • EISSN: 2227-0426



Sepsis, a medical emergency and life-threatening disorder, results from abnormal host response to infection that leads to acute organ dysfunction1. Sepsis is a major killer across all ages and countries and remains the most common cause of admission and death in the Intensive Care Unit (ICU)2. The true incidence remains elusive and estimates of the global burden of sepsis remain a wild guess. One study suggested over 19 million cases and 5 million sepsis-related deaths annually3. Addressing the challenge, the World Health Assembly of the World Health Organisation (WHO) passed a resolution on better prevention, diagnosis, and management of sepsis4. Despite thousands of articles and hundreds of trials, sepsis remains a major killer. The cornerstones of sepsis care remain early recognition, adoption of a systematic evidence-based bundle of care, and timely escalation to higher level of care. The bundle approach has been advocated since 2004 but underwent major modifications in subsequent years with more emphasis on the time-critical nature of sepsis and need to restore physiological variables within one hour of recognition. A shift from a three and six-hour bundle to one-hour bundle has been recommended5. This single hour approach has been faced with an outcry and been challenged6–8. Over several decades, the individual components of the sepsis bundle have not changed. Encountering a patient with suspected sepsis, one should measure lactate, obtain blood cultures, swiftly administer broad spectrum antimicrobials and fluids, and infuse vasopressors. A critical question arises: should we do this for all patients? Sepsis is not septic shock and guidelines did not make distinctive recommendations for each. Septic patients will present differently with some having more subtle signs and symptoms. Phenotypically, we do not know which patient with infection will develop a dysregulated host response and will succumb to sepsis and/or shock6–8. The existing bundle lacks high quality evidence to support its recommendations and a blanket implementation for all patients with ‘suspected’ sepsis could be harmful7. Indeed, a significant reduction of sepsis and septic shock in Australia and New Zealand was observed in a bundle-free region8. Upon arrival in the ED, patients will be triaged. This is ‘time zero’5. Those with hypotension and hypoperfusion will be easily recognised and at most need to receive emergent care. Sepsis, per se, may not manifest clear cut signs and expertise to identify it is required. Those with non-specific symptoms may trigger an early warning scoring system and receive unnecessary antimicrobials and a large volume of intravenous (IV) fluids. Both therapies are not without significant side effects. Putting pressure on ED physicians to implement the 60-minute bundle without individualisation of care puts our patients at risk6–8. Given the heterogenous nature and diverse pathobiological pathways, sepsis diagnosis can be challenging and both over and under-treatment can result. Established biomarkers such as procalcitonin and C-reactive protein lack specificity to rule out infection as the cause of inflammation. Currently, no laboratory test or biomarker helps predict which patients with infection or inflammation will develop organ dysfunction. A dire need for a specific sepsis biomarker exists10.

Modern molecular-based technologies are evolving and utilise polymerase chain reaction (PCR), nanotechnology, and microfluidics for point-of-care testing. Some devices identify causative microorganisms and their sensitivity in less than an hour10. Catecholamines along with IV fluids are indicated to restore perfusion. However, inadvertent side effects may arise, especially at higher doses. Anti-adrenergic ß-blockers improve cardiac performance, enhance receptor responsiveness, and possess anti-inflammatory action. All are desirable in patients with septic shock11.

One randomised trial showed beneficial and protective effects of ß-blockers in septic shock. Rapidly acting titratable agents should be used in conjunction with appropriate hemodynamic monitoring and after adequate volume resuscitation. There is no consensus on target heart rate but an arbitrary cut off of 80–95 beats per minute is reasonable11.

Fluid resuscitation is the cornerstone of sepsis management. There is also compelling evidence that too much fluid is bad. Starch-based colloids should not be used in septic shock. Albumin is an alternative when large volumes are required but is not appropriate in traumatic brain injury. Balanced, less chloride and less acidic crystalloids are safer for the kidneys and are preferred over normal saline. Doses of IV fluids should be tailored to the patient's condition and a 30 ml/kg recommendation should be reviewed.12

Effective sepsis management requires adequate dosing of antimicrobials. Significant alteration of pharmacokinetics and pharmacodynamics is characteristic of septic shock13. Accurate and effective dosing is challenging particularly in patients with multiple comorbidities and those receiving extracorporeal organ support. Underdosing results in treatment failure, whilst overdosing leads to toxicity and the risk of developing multi-drug resistant organisms13. An individualised approach supported by therapeutic drug monitoring is suggested to ensure clinical efficacy13. The search for a cure for sepsis is ongoing. A large prospective, randomised two-arm, parallel group study aims to recruit over 200 patients with septic shock across critical care units in Qatar. Evaluation of Hydrocortisone, Vitamin C, and Thiamine (HYVITS) examines the safety and efficacy of this triple therapy14. Children are particularly vulnerable to sepsis. 1 in 6 children admitted with septic shock to ICU will die. As the majority of paediatric sepsis cases are community acquired, there is a strong need to raise awareness both for families and primary healthcare providers. Akin to adults, a bundle-approach to paediatric sepsis is strongly encouraged. National programs for paediatric sepsis have been established15. The Qatar paediatric multidisciplinary sepsis program was established under the umbrella of the adult programme in 2017. A structured and standardised approach to sepsis across all neonate and paediatric facilities has been developed and implemented. Improvement in timely sepsis recognition and administration of antimicrobials within the golden hour has been observed. The program aims to achieve a 95% compliance to the paediatric sepsis bundle by the end of 2019. A screening tool and order set have been put in place and are presented in this special issue of Qatar Medical Journal16,17. Pregnancy and childbirth are risk factors for sepsis. Multi-organ failure and death can result from puerperal sepsis18. Sepsis is the direct and leading cause of maternal mortality in the UK19. Attention to maternal sepsis with a tailored approach is encouraged. The Qatar National Sepsis Program developed a sepsis care pathway for pregnant women and during their early post-partum period. A broader, national –or better yet– a global approach to further sepsis management and outcome should be considered. There are a number of significant challenges to address. One such challenge is the inconsistency of the operational definition and diagnostic approaches for sepsis including coding and documentation1,3.

Significant deficiencies in healthcare systems have been highlighted by sepsis. This is most obvious in medium- and low-income countries. A major limitation to effective sepsis management is inadequate medical staffing and poor knowledge and awareness of sepsis. Both have a negative impact on sepsis outcome3.

Poor medical facilities in many countries pose significant challenges to sepsis care. Lack of critical care capacity – a global phenomenon – has been linked to poor outcome of sepsis cases and septic shock. This could be attributed to provision of suboptimal critical care, monitoring and critical interventions outside of the ICU. ICU availability is subject to inconsistency and inequity.2,3

Lack of adequate surgical capacity to accomplish timely source control adversely affects sepsis management. This, unfortunately, in medium- and low-income countries, is accompanied by inadequate medical supplies, diagnostic capacity, and manpower which increases sepsis mortality and morbidity3. Antimicrobials are critical for sepsis care. A global concern is the development of multi-drug resistant organisms and the lack of novel antimicrobials and this adds pressure on those caring for septic patients. Effective antimicrobials should be utilised to eradicate infections. Misuse, inadequacy, inferior agents, and lack of timely access to effective and affordable agents significantly hinders patient's recovery from sepsis2,3.

Optimum sepsis outcome mandates attention to acute sepsis complications (e.g. acute renal or respiratory failure) as well as addressing post-discharge complications and disability. These challenging issues remain poorly studied or addressed3. Sepsis and septic shock are major global health concerns. Progress has been achieved in understanding this life-threatening syndrome at a biological, metabolic, and cellular level. Efforts should be coordinated to improve sepsis care. Better and more accurate diagnostics are needed and governments are encouraged to invest in sepsis research and care. More integrated, inclusive, and focused research is desperately needed. Public education and increased awareness among primary healthcare providers are also critical to improve sepsis outcome.


Article metrics loading...

Loading full text...

Full text loading...


  1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315:8:801810.
    [Google Scholar]
  2. Perner A, Gordon AC, De-Backer D, Dimopoulos G, Russell JA, Lipman J, et al.  Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med. 2016; 42:12:19581969.
    [Google Scholar]
  3. Rudd KE, Kissoon N, Limmathurotsakul D, Bory S, Mutahunga B, Seymour CW, et al.  The global burden of sepsis: barriers and potential solutions. Crit Care. 2018; 22:1:232.
    [Google Scholar]
  4. World Health Organisation. Service delivery and safety. Improving the prevention, diagnosis and clinical management of sepsis [Internet]. [Cited 10 June 2019]. Available from: https://www.who.int/servicedeliverysafety/areas/sepsis/en/.
  5. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 Update [Internet]. 2018 [cited 10 June 2019]. Available from http://www.survivingsepsis.org/SiteCollectionDocuments/Surviving-Sepsis-Campaign-Hour-1-Bundle-2018.pdf.
  6. Marik PE, Farkas JD, Spiegel R, Weingart S. POINT: Should the Surviving Sepsis Campaign Guidelines Be Retired? Chest. 2019; 155:1:1214.
    [Google Scholar]
  7. Kalantari A, Rezaie SR. Challenging the One-Hour Sepsis Bundle. West J Emerg Med. 2019; 20:2:185190.
    [Google Scholar]
  8. Spiegel R, Farkas JD, Rola P, Kenny JE, Olusanya S, Marik PE, et al.  The 2018 Surviving Sepsis Campaign's Treatment Bundle: When Guidelines Outpace the Evidence Supporting Their Use. Ann Emerg Med. 2019; 73:4:356358.
    [Google Scholar]
  9. Singer M. Biomarkers for sepsis-past, present and future. Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.8 .
    [Google Scholar]
  10. Singer M. Beta blockers in sepsis. Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.42 .
    [Google Scholar]
  11. Juma B. Intravenous fluid, Is it risky? Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.22 .
    [Google Scholar]
  12. Martin G. Optimal fluid management in sepsis. Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.40 .
    [Google Scholar]
  13. Bakdach D. Implications of pharmacokinetic during sepsis. Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.41 .
    [Google Scholar]
  14. U.S. National Library of Medicine. Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock (HYVITS) [Internet]. 2019 [Cited 2 July 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03380507.
  15. Abboud P. Pediatric Sepsis Updates. Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.21 .
    [Google Scholar]
  16. Labib A, Ashour R. Qatar Paediatric National Sepsis Program; Where Are We? Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.65 .
    [Google Scholar]
  17. Labib A, Ashour R. Paediatric Sepsis Improvement Pathway. Qatar Experience. Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.39 .
    [Google Scholar]
  18. Imran M. Puerperal sepsis and multiple organ dysfunctions caused by Group A streptococcus. Qatar Med J. 2019; 2019:2, Available from: https://www.qscience.com/content/journals/10.5339/qmj.2019.qccc.83 .
    [Google Scholar]
  19. Nuffield Department of Population Health. Severe Maternal Sepsis [Internet]. [Cited 7 July 2019]. Available from: https://www.npeu.ox.ac.uk/ukoss/current-surveillance/ss.
  • Article Type: Editorial
Keyword(s): bundleguidelines and sepsis pathway
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error